De Wit R, Kulkarni GS, Uchio E, et al. Pembrolizumab for High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial. ESMO 2018, abstract 864O.
Darmkanker vaker ontdekt in vroeg stadium, minder operaties en betere overleving
mrt 2024 | Maag-darm-leveroncologie